MapLight Therapeutics, Inc. Operating Cash Flow
MapLight Therapeutics, Inc. (MPLT) reported Operating Cash Flow of -$96.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- MapLight Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$44.87M.
- MapLight Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$51.18M.
- MapLight Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$46.83M.
- MapLight Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$31.79M.
- MapLight Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$138.14M.
- MapLight Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$78.81M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$44.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$96.05M 10-Q · filed 2026-08-13 | -$142.88M derived: sum of 3 quarters · filed 2026-08-13 | -$174.67M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$51.18M 10-Q · filed 2026-05-14 | -$98.01M derived: sum of 2 quarters · filed 2026-05-14 | -$129.80M derived: sum of 3 quarters · filed 2026-05-14 | -$163.76M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$46.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$78.62M derived: sum of 2 quarters · filed 2026-03-26 | -$112.59M derived: sum of 3 quarters · filed 2026-08-13 | -$138.14M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$31.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-04 | -$65.76M derived: sum of 2 quarters · filed 2026-08-13 | -$91.31M 10-Q · filed 2025-12-04 | -$112.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$33.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$59.52M 10-Q · filed 2026-08-13 | -$81.00M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$25.55M 10-Q · filed 2026-05-14 | -$47.04M derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$21.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$78.81M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | -$57.33M 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |